secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2024-12-02T23:59:59+00:00
Accession:  0001140361-24-048184
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 5.03, 2.03, 3.02, 3.03, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Biosciences raises up to $47.6M in Series A preferred stock and warrants private placement
--------------------------------------------------------------------------------

- Issued up to 21,157 shares of Series A Convertible Preferred at $2,250/share, with warrants for up to 31.7M common shares at $2.30.
- Initial closing of $37.6M (16,713 preferred shares) expected Dec 5, 2024; option for additional $9.9M by Dec 27, 2024.
- Series A Preferred carries 18% annual cumulative dividend, convertible into common at $2.25 after stockholder approval.
- Director Omid Farokhzad resigned; Frances Schulz (former EY partner) and Donald Tang (Celadon designee) appointed to board.
- Net proceeds to fund working capital, R&D, and SENTI-202 program advancement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000114036124048184/0001140361-24-048184-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000114036124048184/ef20039400_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-048184

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer